The Role of Methylation Analysis in Distinguishing Cellular Myxoma from Low-Grade Myxofibrosarcoma
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25105105 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Hanna Henzinger und 7 weiteren Autor:innen. Beteiligte Einrichtung: Diagnostic and Research Institute of Pathology, Medical University of Graz, 8010 Graz, Austria. Hauptthemen laut MEDLINE: Myxoma, DNA Methylation, Fibrosarcoma, DNA Copy Number Variations. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: (Förderungsstipendium MEFO Graz) from the Medical University of Graz.
Abstract (Originalsprache)
Cellular myxoma is a benign soft tissue tumor frequently associated with GNAS mutation that may morphologically resemble low-grade myxofibrosarcoma. This study aimed to identify the undescribed methylation profile of cellular myxoma and compare it to myxofibrosarcoma. We performed molecular analysis on twenty cellular myxomas and nine myxofibrosarcomas and analyzed the results using the methylation-based DKFZ sarcoma classifier. A total of 90% of the cellular myxomas had GNAS mutations (four loci had not been previously described). Copy number variations were found in all myxofibrosarcomas but in none of the cellular myxomas. In the classifier, none of the cellular myxomas reached the 0.9 threshold. Unsupervised t-SNE analysis demonstrated that cellular myxomas form their own clusters, distinct from myxofibrosarcomas. Our study shows the diagnostic potential and the limitations of molecular analysis in cases where morphology and immunohistochemistry are not sufficient to distinguish cellular myxoma from myxofibrosarcoma, particularly regarding GNAS wild-type tumors. The DKFZ sarcoma classifier only provided a valid prediction for one myxofibrosarcoma case; this limitation could be improved by training the tool with a more considerable number of cases. Additionally, the classifier should be introduced to a broader spectrum of mesenchymal neoplasms, including benign tumors like cellular myxoma, whose distinct methylation pattern we demonstrated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Diagnostic and Research Institute of Pathology, Medical University of Graz, 8010 Graz, Austria.
- Division of General Radiology, Department of Radiology, Medical University of Graz, 8010 Graz, Austria.
- Department of Orthopedics and Trauma, Medical University of Graz, 8010 Graz, Austria.
- Division of Clinical Oncology, Department of Medicine, Medical University of Graz, 8010 Graz, Austria.
- Institute of Pathology, Ludwig Maximilians University Hospital Munich, 80336 Munich, Germany.
- German Cancer Consortium (DKTK), Partner Site Munich, 80336 Munich, Germany.
ORCID-Profile: Iva Brčić, Jasminka Igrec, Theresa Marie Godschachner, Susanne Scheipl, Bernadette Liegl-Atzwanger
Förderung
- (Förderungsstipendium MEFO Graz) from the Medical University of Graz
Zitieren
APA
Henzinger, H., Brčić, I., Igrec, J., Godschachner, T. M., Scheipl, S., Szkandera, J., Jurmeister, P., & Liegl-Atzwanger, B. (2024). The Role of Methylation Analysis in Distinguishing Cellular Myxoma from Low-Grade Myxofibrosarcoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25105105
Vancouver
Henzinger H, Brčić I, Igrec J, Godschachner TM, Scheipl S, Szkandera J, et al. The Role of Methylation Analysis in Distinguishing Cellular Myxoma from Low-Grade Myxofibrosarcoma. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25105105
BibTeX
@article{Henzinger2024,
author = {Henzinger, Hanna and Brčić, Iva and Igrec, Jasminka and Godschachner, Theresa Marie and Scheipl, Susanne and Szkandera, Joanna and Jurmeister, Philipp and Liegl-Atzwanger, Bernadette},
title = {The Role of Methylation Analysis in Distinguishing Cellular Myxoma from Low-Grade Myxofibrosarcoma},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25105105}
}
EUVIMED